Last updated on December 2018

S0820 Adenoma and Second Primary Prevention Trial


Brief description of study

The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon cancer.

Detailed Study Description

The purpose of this study is to assess whether eflornithine 500 mg or sulindac 150 mg are effective in reducing the 3-year event rate of high risk adenoma or second primary colorectal cancer in Stage 0, I II and III colon cancer patients. The primary hypothesis will test the main effect of each agent, as well as the comparison of placebo alone to the combination of sulindac and eflornithine.

Clinical Study Identifier: NCT01349881

Find a site near you

Start Over

Regions Hospital

Saint Paul, MN United States
0.17miles
  Connect »

United Hospital

Saint Paul, MN United States
1.89miles
  Connect »

Minnesota Oncology Hematology PA-Maplewood

Maplewood, MN United States
5.06miles
  Connect »

Saint John's Hospital - Healtheast

Maplewood, MN United States
5.06miles
  Connect »

University of Minnesota/Masonic Cancer Center

Minneapolis, MN United States
7.13miles
  Connect »

Minnesota Oncology Hematology PA-Woodbury

Woodbury, MN United States
7.52miles
  Connect »

Health Partners Inc

Minneapolis, MN United States
7.54miles
  Connect »

Abbott-Northwestern Hospital

Minneapolis, MN United States
8.12miles
  Connect »

Hennepin County Medical Center

Minneapolis, MN United States
8.36miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.